Annual Financials for Indaptus Therapeutics Inc.
Fiscal year is February-January. All values USD millions. |
2021 | 2020 | 2019 | 2018 | 2017 |
5-year trend |
Sales/Revenue
|
- | - | - | - | - | |
Sales Growth |
- | - | - | - | - | |
Cost of Goods Sold (COGS) incl. D&A |
1,403 | 852 | 854,000 | 859,000 | 829,000 | |
COGS excluding D&A |
- | - | - | - | - | |
Depreciation & Amortization Expense |
- | 852 | - | - | 829,000 | |
Depreciation |
- | 852 | - | - | 829,000 | |
Amortization of Intangibles |
- | - | - | - | - | |
COGS Growth |
- | -39.27% | 100,134.74% | 0.59% | -3.49% | |
Gross Income |
(1,403) | (852) | (854,000) | (859,000) | (829,000) | |
Gross Income Growth |
- | 39.27% | -100,134.74% | -0.59% | 3.49% | |
Gross Profit Margin |
- | - | - | - | - | NA |
|
2021 | 2020 | 2019 | 2018 | 2017 |
5-year trend |
SG&A Expense |
7.73M | 3.6M | 34.09M | 42.47M | 28.61M | |
Research & Development |
- | 2.66M | - | - | 24.3M | |
Other SG&A |
5.2M | 943,396 | 7.43M | 7.07M | 4.32M | |
SGA Growth |
- | -53.43% | 847.42% | 24.57% | -32.63% | |
Other Operating Expense |
- | - | - | - | - | |
Unusual Expense |
- | - | 13.65M | 194,000 | (220,000) | |
EBIT after Unusual Expense |
- | - | (48.6M) | (43.52M) | 220,000 | |
Non Operating Income/Expense |
- | 15,110 | - | - | 70,000 | |
Non-Operating Interest Income |
- | - | - | - | 286,000 | |
Equity in Affiliates (Pretax) |
- | - | - | - | - | |
Interest Expense |
- | - | 15,000 | 23,000 | 17,000 | |
Interest Expense Growth |
- | - | - | 53.33% | -26.09% | |
Gross Interest Expense |
- | - | - | - | 17,000 | |
Interest Capitalized |
- | - | - | - | - | |
Pretax Income |
(7.71M) | (3.58M) | (46.96M) | (43.44M) | (28.88M) | |
Pretax Income Growth |
- | 53.52% | -1,210.24% | 7.50% | 33.52% | |
Pretax Margin |
- | - | - | - | - | NA |
Income Tax |
- | - | 638,000 | 103,000 | 29,000 | |
Income Tax - Current Domestic |
- | - | - | - | - | |
Income Tax - Current Foreign |
- | - | - | - | - | |
Income Tax - Deferred Domestic |
- | - | - | - | - | |
Income Tax - Deferred Foreign |
- | - | - | - | - | |
Income Tax Credits |
- | - | - | - | - | |
Equity in Affiliates |
- | - | - | - | - | |
Other After Tax Income (Expense) |
- | - | - | - | - | |
Consolidated Net Income |
(7.71M) | (3.58M) | (47.6M) | (43.54M) | (28.91M) | |
Minority Interest Expense |
- | - | - | - | - | |
Net Income |
(7.71M) | (3.58M) | (47.6M) | (43.54M) | (28.91M) | |
Net Income Growth |
- | 53.52% | -1,228.04% | 8.52% | 33.61% | |
Net Margin Growth |
- | - | - | - | - | NA |
Extraordinaries & Discontinued Operations |
- | - | - | - | - | |
Extra Items & Gain/Loss Sale Of Assets |
- | - | - | - | - | |
Cumulative Effect - Accounting Chg |
- | - | - | - | - | |
Discontinued Operations |
- | - | - | - | - | |
Net Income After Extraordinaries |
(7.71M) | (3.58M) | (47.6M) | (43.54M) | (28.91M) | |
Preferred Dividends |
- | - | - | - | - | |
Net Income Available to Common |
(7.71M) | (3.58M) | (47.6M) | (43.54M) | (28.91M) | |
EPS (Basic) |
(1.89) | (7.37) | (112.74) | (111.67) | (130.96) | |
EPS (Basic) Growth |
- | -291.06% | -1,429.27% | 0.95% | -17.27% | |
Basic Shares Outstanding |
4.09M | 486,168 | 422,200 | 389,913 | 220,750 | |
EPS (Diluted) |
(1.89) | (7.37) | (112.74) | (111.67) | (130.96) | |
EPS (Diluted) Growth |
- | -291.06% | -1,429.27% | 0.95% | -17.27% | |
Diluted Shares Outstanding |
4.09M | 486,168 | 422,200 | 389,913 | 220,750 | |
EBITDA |
(7.73M) | (3.6M) | (34.09M) | (42.47M) | (28.61M) | |
EBITDA Growth |
- | 53.43% | -847.42% | -24.57% | 32.63% | |
EBITDA Margin |
- | - | - | - | - | NA |